Diadema Partners’s Eli Lilly LLY Stock Holding History

Diadema Partners’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,000	Closed	-$6.13M	–	177
2026 Q1	$5.52M	Buy	6,000 +4,000	+200%	+$4.06M	0.94%	36
2025 Q4	$2.15M	Buy	+2,000	New	+$1.91M	0.37%	61
2025 Q3	–	Sell	-14,816	Closed	-$11M	–	147
2025 Q2	$11.5M	Sell	14,816 -4,486	-23%	-$3.49M	3.52%	7
2025 Q1	$15.9M	Buy	+19,302	New	+$16.1M	4.16%	7

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Diadema Partners's LLY Position: Q2 2026 in Review

Diadema Partners sold out of Eli Lilly (LLY) in Q2 2026, closing a stake of 6,000 shares — an estimated $6.13M sold.

Diadema Partners first reported a position in LLY in Q1 2025 and held it in 4 quarters. The position peaked at $15.9M in Q1 2025. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

Diadema Partners reported no remaining Eli Lilly position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 6,000 Eli Lilly shares in Q2 2026, an estimated $6.13M.
Diadema Partners first reported a position in Eli Lilly in Q1 2025 and held it in 4 quarters.
Diadema Partners's Eli Lilly position peaked at $15.9M in Q1 2025.
4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.